Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / CCL18



This biomarker is also known as:
  • pulmonary and activation-regulated chemokine,
  • AMAC1,
  • DC-CK1,
  • chemokine (C-C), dendritic,
  • Pulmonary and activation-regulated chemokine,
  • AMAC-1,
  • chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated),
  • MIP4,
  • SCYA18,
  • Small-inducible cytokine A18,
  • C-C motif chemokine 18,
  • small-inducible cytokine A18,
  • macrophage inflammatory protein 4,
  • Dendritic cell chemokine 1,
  • DCCK1,
  • alternative macrophage activation-associated CC chemokine 1,
  • Alternative macrophage activation-associated CC chemokine 1,
  • dendritic cell chemokine 1,
  • PARC,
  • MIP-4,
  • small inducible cytokine A18,
  • CC chemokine PARC,
  • CKb7,
  • CC chemokine ligand 18,
  • Macrophage inflammatory protein 4,
  • small inducible cytokine subfamily A (Cys-Cys), member 18, pulmonary and activation-regulated,

View in BioMuta


CCL18, also known as MIP-4, is a member of the cytokine family, a family of secreted proteins involved in immunoregulatory and inflammatory processes. CCL18 is a Cys-Cys (CC) cytokine, characterized by two adjacent cysteines. CCL18 is a chemotactic factor that attracts lymphocytes but not monocytes or granulocytes. This chemokine attracts naive T lymphocytes toward dendritic cells and activated macrophages in lymph nodes. It may play a role in both humoral and cell-mediated immunity responses.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: CCL18


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


CCL18 has been described in the literature as a potential biomarker for ovarian, bladder, breast, and colorectal cancer. CCL18 has not been identified previously in serum as a lung cancer biomarker, but it was observed up-regulated in lung cancer in the aptamer proteomic technology study (Ostroff et al, 2010).

Performance Comment

CCL18, also known as MIP-4, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.